Skin appendage disorders · 2021
Certolizumab Pegol: A New Therapeutic Approach for Acrodermatitis Continua of Hallopeau.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rizzetto Giulio, Diotallevi Federico, Molinelli Elisa, Radi Giulia, Offidani Anna Maria
Аннотация
INTRODUCTION: Acrodermatitis continua of Hallopeau (ACH) is a rare, chronic, and recurrent form of pustular psoriasis (PP) localized to one or more digits. Due to the rarity of ACH, no clear treatment guidelines are currently available, making the therapeutic approach more complex.
CASE PRESENTATION: We report the first case of a young woman with ACH who was successfully treated with certolizumab pegol (CZP).
DISCUSSION/CONCLUSION: PP and ACH are difficult to treat, and biologics may be an option more manageable than cyclosporine. CZP is the safest biologic therapy during pregnancy, so there is low risk in prescribing it in women with childbearing potential. However, continuing biological therapy during pregnancy always involves an assessment of the clinical benefits, which must outweigh the risks.
CASE PRESENTATION: We report the first case of a young woman with ACH who was successfully treated with certolizumab pegol (CZP).
DISCUSSION/CONCLUSION: PP and ACH are difficult to treat, and biologics may be an option more manageable than cyclosporine. CZP is the safest biologic therapy during pregnancy, so there is low risk in prescribing it in women with childbearing potential. However, continuing biological therapy during pregnancy always involves an assessment of the clinical benefits, which must outweigh the risks.